🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

CTXR CTXR

Company Profile ↓
$0.78
-43.82% 1Y
P/E-0.23
52W High$1.82
52W Low$0.48
EPS (TTM)$-3.38

Company Overview

CTXR (CTXR) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Growth & Price Performance

Stock Price Performance

1 Year:-43.82%
6 Months:-0.27%
3 Months:+13.67%
1 Month:+33.72%
Technical Snapshot Mixed
52-Week Range 22% of range
$0.48 $1.82
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)70.25 · Overbought
Price Performance
1M+33.72%
3M+13.67%
6M-0.27%
1Y-43.82%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading 57.1% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.23
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-44.79%
ROE
-55.42%
ROA
-28.59%
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.95
EPS (TTM)
$-3.38

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$132.54M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
1.80%
Chg in Prom Hold
-
FII / Inst Holding
4.16%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$0
EBITDA
$-38.20M
Free Cash Flow
$-24.26M
Operating Cash Flow
$-26.55M
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2013Jun 2013Dec 2013Mar 2014Jun 2014Dec 2014Mar 2015Jun 2015Dec 2015Mar 2016Jun 2016Dec 2016Mar 2017Jun 2017Dec 2017Mar 2018Jun 2018Dec 2018Mar 2019Jun 2019Dec 2019Mar 2020Jun 2020Dec 2020Mar 2021Jun 2021Dec 2021Mar 2022Jun 2022Dec 2022Mar 2023Jun 2023Dec 2023Mar 2024Jun 2024Dec 2024Mar 2025Jun 2025Dec 2025Mar 2026
Revenue 00000---------------------------------3.94M1.67M
Gross Profit --------------------------------------3.15M1.34M
Operating Income -9.34K-3.44K-499.19K-49.83K-1.30K-878.90K-608.91K-773.73K-1.24M-671.61K-2.13M-2.78M-2.54M-2.26M-3.24M-4.87M-2.02M-3.87M-3.64M-4.43M-4.45M-4.43M-4.69M-8.16M-4.19M-5.98M-9.26M-7.59M-8.92M-7.25M-10.69M-8.67M-9.34M-10.97M-10.63M-10.04M-11.26M-8.79M-9.02M-32.19M
Net Income -10.23K-4.43K-534.41K-90.28K-34.88K-823.71K-345.27K-824.97K-1.22M-869.45K-3.62M-2.18M-2.74M-2.42M-3.25M-4.42M-2.02M-3.87M-3.63M-4.41M-4.32M-4.42M-4.68M-8.15M-4.12M-5.82M-9.23M-7.56M-8.86M-3.59M-10.53M-8.48M9.23M-8.54M-10.57M-10.28M-11.51M---
Diluted EPS 0.000.000.000.000.00---------------------0.05-0.06-0.05-0.06-0.02-0.07-0.06-1.45-1.34-1.57-1.30-1.27-0.80-0.38-0.95
R&D Expense --437.40K--477.12K282.24K415.53K829.16K-200.30K381.12K1.41M859.91K190.65K606.52K3.44M778.86K2.11M1.70M2.77M2.66M2.02M2.64M6.19M1.55M2.20M5.46M3.45M4.89M3.45M4.73M3.76M2.62M3.61M2.76M2.13M3.77M1.62M1.60M1.63M

Profit & Loss (Annual)

Figures in USD.

Metric Sep 2010Sep 2011Sep 2012Sep 2013Dec 2013Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Revenue -000----50.00K75.00K90.00K90.00K-0000
Cost of Revenue -----------------
Gross Profit -----------------
Operating Expenses -------------33.32M36.73M42.00M38.53M
Operating Income --25.64K-19.62K-28.12K-1.18M-653.80K-3.23M-7.45M-9.99M-13.79M-15.60M-17.71M--33.32M-36.73M-42.00M-38.53M
EBITDA --------------33.14M-36.54M-41.79M-38.20M
Interest Expense ------------10.84K0--267.78K
Pretax Income --------------33.06M-31.97M-38.85M-38.68M
Tax Provision -------------576.00K576.00K576.00K1.06M
Net Income -15.50K-26.34K-22.01K-31.37K-1.29M-737.73K-2.90M-8.30M-10.38M-12.54M-15.56M-17.55M--33.64M-32.54M-39.14M-37.43M
Diluted EPS -0.000.000.00----------5.75-5.57-5.97-3.38
R&D Expense ----492.14K5741.80M2.93M2.94M6.56M8.60M8.81M12.24M17.66M14.82M11.91M9.16M

Balance Sheet (Annual)

Figures in USD.

Metric Sep 2010Jun 2011Sep 2011Sep 2012Dec 2012Sep 2013Dec 2013Sep 2014Sep 2015Jun 2016Sep 2016Sep 2017Sep 2018Sep 2019Sep 2020Oct 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Total Assets 2.50K-212135-0-1.56M741.54K-21.95M24.42M31.05M36.75M43.77M-142.43M114.00M103.61M116.65M130.94M
Total Equity 2.50K-23.84K-23.84K-45.85K-1.61M-14.69K-2.90M-741.93K-635.21K-16.77M21.95M30.64M27.15M33.67M33.67M132.18M102.83M90.83M70.08M67.55M
Cash & Equivalents 0-21213541.66K054.39K1.55M676.14K1.63M294.35K3.20M9.18M7.89M13.86M-70.07M41.71M26.48M3.25M4.25M
Total Liabilities -------------9.59M10.10M-9.65M10.57M12.18M42.55M53.41M
Current Liabilities --24.05K45.98K-14.69K-2.30M1.38M-5.18M2.47M3.18M4.61M4.10M-3.98M4.53M5.78M35.81M44.91M

Cash Flows (Annual)

Figures in USD.

Metric Sep 2011Sep 2012Sep 2013Dec 2013Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Operating Cash Flow -20.78K-20.32K-20.60K-1.10M-183.16K-2.39M-5.90M-7.97M-11.32M-12.44M-16.93M-24.25M-28.36M-29.06M-28.20M-26.55M
Investing Cash Flow 000---255.75K-2.13K---1.83K-40.01M---5.00M-5.75M
Financing Cash Flow 18.49K20.25K20.47K1.11M1.68M1.51M5.26M10.88M17.30M11.15M22.90M120.47M-13.83M9.97M33.30M
Capital Expenditure --------2.13K---1.83K-6.94K----
Free Cash Flow --------7.97M---16.93M-24.26M----

Ratios (Annual)

Figures in %.

Metric Sep 2010Sep 2011Sep 2012Sep 2013Dec 2013Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Gross Margin % -----------------
Operating Margin % ---------19,972.6%-18,385.5%-17,331.5%-19,678.5%-----
Net Margin % ---------20,769.9%-16,715.5%-17,291.3%-19,497.9%-----
ROE % -620.0%110.5%48.0%213.5%44.4%99.4%456.9%-49.5%-47.3%-40.9%-57.3%-52.1%--32.7%-35.8%-55.9%-55.4%
ROCE % -107.5%42.8%191.4%-88.1%508.5%-44.4%-45.5%-49.5%-48.5%-44.6%--30.4%-37.5%-52.0%-44.8%

Shareholding Pattern

Insiders
1.80%
Institutions
4.16%
Public Float
4.23%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CTXR

Google News Fri, 31 Jul 2026

Citius Pharmaceuticals Stock Price Forecast. Should You Buy CTXR? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTFBrQk9fc0FSREs0Q1hQZEJTUm04dldzT2ZELVRjTTF3eVBwSmlsRm9fNkJUQlRuOTNMam5YUzdLMjd1LWhVb09NVw?oc=5" target="_blank">Citius Pharmaceuticals Stock Price Forecast. Should You Buy CTXR?</a>…

Google News Fri, 15 May 2026

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire

<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxNSkZxSnRrbFFPWThNUElQOHU2UTRpOWZyOWFQM0d1TGFaSHZ3ZUdsSVBXelJsMjdYRFFtTEZ0d3gtNnpMUXhlbDNZSEQ4ei1RV000VXNSN1FkM0E4dDdHNTRmRlJBS1otQ0gtaGdQTHpXUmVhdDUzaXZmVFRUMHQ2ajR1OUp4Tl95amI2YT…

Google News Sun, 24 May 2026

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOVDAxTDFILU9FYTZzaUhHQjJHUXhxMEFHeHowTzMtZWZ4QnJ3ZWZ0QnVtOHk4cnp1SzdwYzQzSnd1Z3dBWGpIUHNtV2xMSWxWWWdlTHRfa1Y2QW84Z3RzejJZbHluTUZhdWFmWlA2M2kwMmdtSVowZ19ubDZYZHRsV0ZhUnpEQVFRdklzVm…

Google News hu, 25 Jun 2026

CTXR Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE53clE3ZlBvYVd6M0dTZ1laUVlQeUtWUEdRRXRaUUtFN0VmQXh1WDJMNmppeUxPNG9qaHgwbTVjVEdtNFVaR29xZ3pZWkpmamFJckVYRHVKd3NLNC1fbGMxRkRZb3J0RTJscFNaNVlfRE9WbDNaMnVycTdR?oc=5" target="_blank">CTX…

Google News hu, 28 May 2026

Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPRXV6RkZiN0N5SVEtMmVMZ0JLTjVYdDNNaFIyQTkxaTlBTk5zN3FIYUNySGFVVmlFOEF1NG1kX3NiU1RTdzk3WkZFMThPNnc5VlFSUnlrVngtb1hncnVHanR1ODlIN0VsbFBLMmhidXB4bncxYUJjclFJbTZQVmxhX3c2cmdmUVZZcnMyem…

Google News Sat, 28 Feb 2026

CTXR Should I Buy - Intellectia AI

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE15VHByQW82YVBJRTJtbDJHRmJYemVuLUNYNzR4bzRGbmF5NXdMUGJLOW43dU1nandVcmtjelk5ZUxjX3hIblFVa2s4UnlsVFo5aUpVRnlhVTViUGRZZkE?oc=5" target="_blank">CTXR Should I Buy</a>&nbsp;&nbsp;<font c…

CTXR — Frequently Asked Questions

What is the current share price of CTXR?

As of 2026-08-05 17:25 PDT, CTXR trades at $0.78 on NASDAQ/NYSE. Its 52-week range is $0.48 to $1.82.

What is the P/E ratio of CTXR?

CTXR trades at a trailing price-to-earnings (P/E) ratio of -0.23.

What is the return on equity (ROE) of CTXR?

CTXR has a return on equity (ROE) of -55.42%. Its return on capital employed (ROCE) is -44.79%.

Is CTXR a good stock to buy?

This page provides a data-driven analysis of CTXR, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space